-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Minova (603538.SH) issued an announcement. Ningbo Menohua Tiankang Pharmaceutical Co., Ltd. (hereinafter referred to as “Menohua Tiankang”), a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for febuastat tablets approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”). Drug indications: Suitable for long-term treatment of hyperuricemia in patients with gout.

Zhitongcaijing·12/10/2025 09:09:05
Listen to the news
Zhitong Finance App News, Minova (603538.SH) issued an announcement. Ningbo Menohua Tiankang Pharmaceutical Co., Ltd. (hereinafter referred to as “Menohua Tiankang”), a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for febuastat tablets approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”). Drug indications: Suitable for long-term treatment of hyperuricemia in patients with gout.